<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id><journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id><journal-title-group><journal-title>Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0033-3158</issn><issn pub-type="epub">1432-2072</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27714429</article-id><article-id pub-id-type="pmc">5420386</article-id><article-id pub-id-type="publisher-id">4453</article-id><article-id pub-id-type="doi">10.1007/s00213-016-4453-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Alterations of consciousness and mystical-type experiences after acute LSD in humans</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Liechti</surname><given-names>Matthias E.</given-names></name><address><phone>+41 61 328 68 68</phone><email>matthias.liechti@usb.ch</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dolder</surname><given-names>Patrick C.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Schmid</surname><given-names>Yasmin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0642</institution-id><institution-id institution-id-type="GRID">grid.6612.3</institution-id><institution>Psychopharmacology Research, Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, </institution><institution>University of Basel, </institution></institution-wrap>Hebelstrasse 2, CH-4031 Basel, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>234</volume><issue>9</issue><fpage>1499</fpage><lpage>1510</lpage><history><date date-type="received"><day>25</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>27</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Rationale</title><p>Lysergic acid diethylamide (LSD) is used recreationally and in clinical research. Acute mystical-type experiences that are acutely induced by hallucinogens are thought to contribute to their potential therapeutic effects. However, no data have been reported on LSD-induced mystical experiences and their relationship to alterations of consciousness. Additionally, LSD dose- and concentration-response functions with regard to alterations of consciousness are lacking.</p></sec><sec><title>Methods</title><p>We conducted two placebo-controlled, double-blind, cross-over studies using oral administration of 100 and 200&#x000a0;&#x003bc;g LSD in 24 and 16 subjects, respectively. Acute effects of LSD were assessed using the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale after both doses and the Mystical Experience Questionnaire (MEQ) after 200&#x000a0;&#x003bc;g.</p></sec><sec><title>Results</title><p>On the MEQ, 200&#x000a0;&#x003bc;g LSD induced mystical experiences that were comparable to those in patients who underwent LSD-assisted psychotherapy but were fewer than those reported for psilocybin in healthy subjects or patients. On the 5D-ASC scale, LSD produced higher ratings of blissful state, insightfulness, and changed meaning of percepts after 200&#x000a0;&#x003bc;g compared with 100&#x000a0;&#x003bc;g. Plasma levels of LSD were not positively correlated with its effects, with the exception of ego dissolution at 100&#x000a0;&#x003bc;g.</p></sec><sec><title>Conclusions</title><p>Mystical-type experiences were infrequent after LSD, possibly because of the set and setting used in the present study. LSD may produce greater or different alterations of consciousness at 200&#x000a0;&#x003bc;g (i.e., a dose that is currently used in psychotherapy in Switzerland) compared with 100&#x000a0;&#x003bc;g (i.e., a dose used in imaging studies). Ego dissolution may reflect plasma levels of LSD, whereas more robustly induced effects of LSD may not result in such associations.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00213-016-4453-0) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>LSD</kwd><kwd>Altered states of consciousness</kwd><kwd>Mystical experiences</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Lysergic acid diethylamide (LSD) is the prototypical hallucinogen (Nichols <xref ref-type="bibr" rid="CR36">2016</xref>; Passie et al. <xref ref-type="bibr" rid="CR39">2008</xref>). LSD became famous, with a high cultural influence, in the 1960s. LSD continues to be used for recreational and personal purposes (Krebs and Johansen <xref ref-type="bibr" rid="CR31">2013</xref>). Additionally, there is much interest in its therapeutic potential (Baumeister et al. <xref ref-type="bibr" rid="CR2">2014</xref>; Davenport <xref ref-type="bibr" rid="CR8">2016</xref>; Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>; Gasser et al. <xref ref-type="bibr" rid="CR16">2015</xref>; Krebs and Johansen <xref ref-type="bibr" rid="CR30">2012</xref>; Kupferschmidt <xref ref-type="bibr" rid="CR32">2014</xref>). Only one modern study has tested the therapeutic effects of LSD in patients (Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>), whereas several clinical trials have recently evaluated the therapeutic potential of psilocybin (Bogenschutz et al. <xref ref-type="bibr" rid="CR3">2015</xref>; Carhart-Harris et al. <xref ref-type="bibr" rid="CR5">2016a</xref>; Garcia-Romeu et al. <xref ref-type="bibr" rid="CR14">2015</xref>; Griffiths <xref ref-type="bibr" rid="CR18">2016</xref>; Grob et al. <xref ref-type="bibr" rid="CR22">2011</xref>; Guss <xref ref-type="bibr" rid="CR23">2016</xref>), a similar serotonergic hallucinogen (Rickli et al. <xref ref-type="bibr" rid="CR40">2016</xref>). A series of studies showed that psilocybin acutely induced mystical experiences in healthy subjects and patients (Garcia-Romeu et al. <xref ref-type="bibr" rid="CR14">2015</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR20">2008</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR21">2011</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>; MacLean et al. <xref ref-type="bibr" rid="CR34">2011</xref>). Additionally, greater acute effects of psilocybin on the Mystical Experience Questionnaire (MEQ; Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>; MacLean et al. <xref ref-type="bibr" rid="CR35">2012</xref>) were associated with positive long-term effects on mood and personality in healthy subjects (Griffiths et al. <xref ref-type="bibr" rid="CR20">2008</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR21">2011</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>; MacLean et al. <xref ref-type="bibr" rid="CR34">2011</xref>) and better therapeutic outcomes in patients with anxiety, depression, and substance use disorder (Garcia-Romeu et al. <xref ref-type="bibr" rid="CR14">2015</xref>; Griffiths <xref ref-type="bibr" rid="CR18">2016</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR20">2008</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR21">2011</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>; MacLean et al. <xref ref-type="bibr" rid="CR34">2011</xref>). Early studies reported on mystical experiences after experimental administration of LSD, but methodological details are missing (Turek et al. <xref ref-type="bibr" rid="CR51">1974</xref>). Whether and the extent to which LSD produces mystical-type effects in the MEQ are currently unknown. Therefore, we characterized the effects of 200&#x000a0;&#x003bc;g LSD on the MEQ and evaluated the way in which mystical experiences are related to LSD-induced increases in 5 Dimensions of Altered States of Consciousness (5D-ASC) scale scores and plasma levels of LSD.</p><p>Clinical experimental research with LSD has recently seen a resurgence (Carhart-Harris et al. <xref ref-type="bibr" rid="CR6">2016b</xref>; Carhart-Harris et al. <xref ref-type="bibr" rid="CR4">2015</xref>; Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>; Dolder et al. <xref ref-type="bibr" rid="CR12">2015b</xref>; Dolder et al. <xref ref-type="bibr" rid="CR13">2016</xref>; Kaelen et al. <xref ref-type="bibr" rid="CR28">2015</xref>; Kaelen et al. <xref ref-type="bibr" rid="CR29">2016</xref>; Lebedev et al. <xref ref-type="bibr" rid="CR33">2016</xref>; Roseman et al. <xref ref-type="bibr" rid="CR41">2016</xref>; Schmid et al. <xref ref-type="bibr" rid="CR43">2015</xref>; Speth et al. <xref ref-type="bibr" rid="CR44">2016</xref>; Strajhar et al. <xref ref-type="bibr" rid="CR46">2016</xref>; Tagliazucchi et al. <xref ref-type="bibr" rid="CR49">2016</xref>; Terhune et al. <xref ref-type="bibr" rid="CR50">2016</xref>). An increasing amount of data has been generated on the effects of LSD (75&#x000a0;&#x003bc;g) on various neuronal correlates of brain activation (Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>; Kaelen et al. <xref ref-type="bibr" rid="CR29">2016</xref>; Lebedev et al. <xref ref-type="bibr" rid="CR33">2016</xref>; Roseman et al. <xref ref-type="bibr" rid="CR41">2016</xref>). Researchers have correlated subjective drug effects with brain functional magnetic resonance imaging (fMRI) data (Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>; Kaelen et al. <xref ref-type="bibr" rid="CR29">2016</xref>; Lebedev et al. <xref ref-type="bibr" rid="CR33">2016</xref>; Roseman et al. <xref ref-type="bibr" rid="CR41">2016</xref>). This approach likely produces significant findings for subjective effects that show large between-subject variance but not for subjective effects of the substance that are consistently present in all subjects. Lower doses of LSD may also result in more variable responses across subjects compared with higher doses. Furthermore, higher doses of LSD (e.g., 200&#x000a0;&#x003bc;g) that are currently used therapeutically (Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>) may produce more pronounced but also qualitatively different subjective effects (Dolder et al. <xref ref-type="bibr" rid="CR13">2016</xref>). Importantly, plasma concentrations of LSD have not been determined in any of the published LSD fMRI studies to date; therefore, unclear is the way in which LSD exposure in the body is linked to subjective effects in these studies. Therefore, a second goal of the present study was to describe the subjective peak effects of two doses of LSD (100 and 200&#x000a0;&#x003bc;g) using the 5D-ASC scale (Studerus et al. <xref ref-type="bibr" rid="CR47">2010</xref>). The 5D-ASC scale has been used in all of the recent experimental studies with LSD (Carhart-Harris et al. <xref ref-type="bibr" rid="CR6">2016b</xref>; Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>; Schmid et al. <xref ref-type="bibr" rid="CR43">2015</xref>; Tagliazucchi et al. <xref ref-type="bibr" rid="CR49">2016</xref>) and with many other psychedelics, providing an opportunity to compare findings between studies and across substances and research groups. Thus, the present study assessed LSD dose- and plasma concentration-response functions using the 5D-ASC scale in 40 subjects (Dolder et al. <xref ref-type="bibr" rid="CR12">2015b</xref>; Dolder et al. <xref ref-type="bibr" rid="CR13">2016</xref>; Schmid et al. <xref ref-type="bibr" rid="CR43">2015</xref>), thus allowing comparisons with other studies that used the 5D-ASC scale but did not determine plasma LSD concentrations (Carhart-Harris et al. <xref ref-type="bibr" rid="CR6">2016b</xref>; Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>; Kaelen et al. <xref ref-type="bibr" rid="CR29">2016</xref>; Lebedev et al. <xref ref-type="bibr" rid="CR33">2016</xref>; Roseman et al. <xref ref-type="bibr" rid="CR41">2016</xref>; Speth et al. <xref ref-type="bibr" rid="CR44">2016</xref>; Tagliazucchi et al. <xref ref-type="bibr" rid="CR49">2016</xref>; Terhune et al. <xref ref-type="bibr" rid="CR50">2016</xref>). A third goal of the present study was to assess associations across subjects between the peak and total plasma exposure to LSD and its effects on 5D-ASC scale scores (Studerus et al. <xref ref-type="bibr" rid="CR47">2010</xref>). The effects of 100&#x000a0;&#x003bc;g LSD on 5D-ASC scale scores are reported for the first time in the present study, whereas the effects of 200&#x000a0;&#x003bc;g have been previously published (Schmid et al. <xref ref-type="bibr" rid="CR43">2015</xref>). However, the latter study did not evaluate dose- or concentration-response functions. Other data that were generated in the present study have been previously reported including acute and subacute adverse effects (Dolder et al. <xref ref-type="bibr" rid="CR12">2015b</xref>; Dolder et al. <xref ref-type="bibr" rid="CR13">2016</xref>; Schmid et al. <xref ref-type="bibr" rid="CR43">2015</xref>; Strajhar et al. <xref ref-type="bibr" rid="CR46">2016</xref>).</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Material and methods</title><sec id="Sec3"><title>Study design</title><p>We performed two similar studies using double-blind, placebo-controlled, cross-over designs with two experimental test sessions (LSD and placebo) in a balanced order. Study 1 used a dose of 100&#x000a0;&#x003bc;g LSD and placebo in 24 subjects. Study 2 used 200&#x000a0;&#x003bc;g LSD and placebo in 16 subjects. The washout periods between sessions were at least 7&#x000a0;days. The studies were conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee. The administration of LSD to healthy subjects was authorized by the Swiss Federal Office for Public Health, Bern, Switzerland. All of the subjects provided written consent before participating in either of the studies, and they were paid for their participation. The studies were registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> (NCT02308969, NCT01878942).</p></sec><sec id="Sec4"><title>Participants</title><p>Forty healthy participants were recruited from the University of Basel campus via online advertisement. Twenty-four subjects (12 men, 12 women; 33&#x000a0;&#x000b1;&#x000a0;11&#x000a0;years old [mean&#x000a0;&#x000b1;&#x000a0;SD]; range, 25&#x02013;60&#x000a0;years) participated in study 1, and 16 subjects (8 men, 8 women; 29&#x000a0;&#x000b1;&#x000a0;6&#x000a0;years old; range, 25&#x02013;51&#x000a0;years) participated in study 2. The inclusion and exclusion criteria were identical for both studies. Subjects younger than 25&#x000a0;years of age were excluded from participating in the study. Additional exclusion criteria were age &#x0003e;65&#x000a0;years, pregnancy (urine pregnancy test at screening and before each test session), personal or family (first-degree relative) history of major psychiatric disorders (assessed by the semi-structured clinical interview for <italic>Diagnostic and Statistical Manual of Mental Disorders</italic>, 4th edition, Axis I disorders by the study physician and an additional interview by a trained psychiatrist), use of medications that may interfere with the study medication, chronic or acute physical illness (abnormal physical exam, electrocardiogram, or hematological and chemical blood analyses), tobacco smoking (&#x0003e;10 cigarettes/day), lifetime prevalence of illicit drug use &#x0003e;10 times (except for tetrahydrocannabinol), illicit drug use within the last 2&#x000a0;months, and illicit drug use during the study (determined by urine drug tests). The subjects were asked to abstain from excessive alcohol consumption between test sessions and particularly limit their use to one standard drink on the day before the test sessions. Additionally, the participants were not allowed to drink xanthine-containing liquids after midnight before the study day. Eleven subjects had used a hallucinogen, including LSD (six participants), one to three times, and most of the subjects (29) were hallucinogen-naive. We performed urine drug tests at screening and before each test session, and no substances were detected during the study.</p></sec><sec id="Sec5"><title>Study procedures</title><p>Each study included a screening visit, a psychiatric interview, two 25-h experimental sessions, and an end-of-study visit. The experimental sessions were conducted in a quiet standard hospital patient room. The participants were resting in hospital beds except when going to the restroom. Only one research subject and one or two investigators were present during the experimental sessions. The participants could interact with the investigator, rest quietly, and/or listen to music via headphones, but no other entertainment was provided. LSD or placebo was administered at 9:00 AM. The subjects were never alone during the first 12&#x000a0;h after drug administration, and the investigator was in a room next to the subject for up to 24&#x000a0;h while the subjects were asleep (mostly from 1:00 AM to 8:00 AM).</p></sec><sec id="Sec6"><title>Study drug</title><p>LSD (<italic>d</italic>-LSD hydrate, HPLC purity &#x0003e;99&#x000a0;%, Lipomed AG, Arlesheim, Switzerland) was administered in single oral doses of 100 or 200&#x000a0;&#x003bc;g as gelatin capsules. Note that these LSD hydrate doses correspond to LSD tartrate doses of 123 and 246&#x000a0;&#x003bc;g, respectively. In the 1960&#x02013;1970s, small doses of LSD tartrate of 25&#x02013;150&#x000a0;&#x003bc;g were typically used in &#x0201c;psycholytic therapy&#x0201d; and higher doses of &#x0003e;200&#x000a0;&#x003bc;g in &#x0201c;psychedelic&#x0201d; therapy (Pahnke et al. <xref ref-type="bibr" rid="CR38">1970</xref>). The dose used in a recent LSD-assisted psychotherapy study was 200&#x000a0;&#x003bc;g LSD hydrate (Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>). Both doses used in the present study were within the range of doses that are taken for recreational purposes (Passie et al. <xref ref-type="bibr" rid="CR39">2008</xref>). Corresponding placebo capsules were used.</p></sec><sec id="Sec7"><title>Measures</title><sec id="FPar1"><title>Mystical-type experiences</title><p>In study 2, mystical experiences were assessed using a German version (Supplementary Appendix <xref rid="MOESM1" ref-type="media">1</xref>) of the 43-item MEQ (Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>; MacLean et al. <xref ref-type="bibr" rid="CR35">2012</xref>; Pahnke <xref ref-type="bibr" rid="CR37">1969</xref>) embedded in the 100-item States of Consciousness Questionnaire (SOCQ; (Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>). The original English questionnaire was independently forward-translated into German by two translators with German as their mother tongue. Discrepancies between the two forward-translated versions and a previous German version were then discussed and selected items backtranslated. The version was then pretested for comprehension by persons with previous LSD or MDMA use.</p><p>The MEQ has been used in numerous experimental and therapeutic trials with psilocybin (Garcia-Romeu et al. <xref ref-type="bibr" rid="CR14">2015</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR20">2008</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR21">2011</xref>; Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>; MacLean et al. <xref ref-type="bibr" rid="CR34">2011</xref>). The MEQ items provide scale scores for each of seven domains of mystical experiences: internal unity, external unity, sacredness, noetic quality (as real as or more real than everyday reality), deeply felt positive mood, transcendence of time and space, and ineffability/paradoxicality (difficulty describing the experience in words). The total of all scale scores was used as an overall measure of the mystical-type experience. We also derived the four scale scores of the newly validated revised 30-item MEQ: mystical, positive mood, transcendence of time and space, and ineffability (Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>). A complete mystical experience was defined as scores &#x02265;60&#x000a0;% on all MEQ30 factors (Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>). The MEQ was administered 24&#x000a0;h after drug administration, and the participants were asked to retrospectively rate drug effects during peak drug effects. For comparison, we included MEQ ratings that were obtained 6&#x000a0;h after administration of 3,4-methylenedioxymethamphetamine (MDMA) and methylphenidate in another study using a similar research setting (Schmid et al. <xref ref-type="bibr" rid="CR42">2014</xref>). Additionally, we included MEQ ratings from patients who were treated with 200&#x000a0;&#x003bc;g LSD for anxiety related to life-threatening illness in another study (Diesch <xref ref-type="bibr" rid="CR9">2015</xref>; Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>; Gasser et al. <xref ref-type="bibr" rid="CR16">2015</xref>). All of these additional MEQ findings have not been previously published in scientific journals and were obtained in studies that were previously described in detail (Diesch <xref ref-type="bibr" rid="CR9">2015</xref>; Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>; Gasser et al. <xref ref-type="bibr" rid="CR16">2015</xref>; Schmid et al. <xref ref-type="bibr" rid="CR42">2014</xref>).</p></sec><sec id="FPar2"><title>Alterations of consciousness</title><p>The 5D-ASC scale was used in both studies to assess the overall peak alterations of consciousness. The 5D-ASC scale measures altered states of consciousness and contains 94 items (visual analog scales). The instrument consists of five subscales/dimensions (Dittrich <xref ref-type="bibr" rid="CR10">1998</xref>) and 11 lower-order scales (Studerus et al. <xref ref-type="bibr" rid="CR47">2010</xref>). The 5D-ASC dimension &#x0201c;Oceanic Boundlessness&#x0201d; (27 items) measures derealization and depersonalization associated with positive emotional states, ranging from heightened mood to euphoric exaltation. The corresponding lower-order scales include &#x0201c;experience of unity,&#x0201d; &#x0201c;spiritual experience,&#x0201d; &#x0201c;blissful state,&#x0201d; and &#x0201c;insightfulness.&#x0201d; The dimension &#x0201c;Anxious Ego Dissolution&#x0201d; (21 items) summarizes ego disintegration and loss of self-control phenomena associated with anxiety. The corresponding lower-order scales include &#x0201c;disembodiment,&#x0201d; &#x0201c;impaired control of cognition,&#x0201d; and &#x0201c;anxiety.&#x0201d; The dimension &#x0201c;Visionary Restructuralization&#x0201d; (18 items) consists of the lower-order scales &#x0201c;complex imagery,&#x0201d; &#x0201c;elementary imagery,&#x0201d; &#x0201c;audio-visual synesthesia,&#x0201d; and &#x0201c;changed meaning of percepts.&#x0201d; Two additional dimensions describe &#x0201c;Auditory Alterations&#x0201d; (15 items) and &#x0201c;Reduction of Vigilance&#x0201d; (12 items). The scale is well-validated and widely used to characterize the subjective effects of various psychedelic drugs (Carhart-Harris et al. <xref ref-type="bibr" rid="CR6">2016b</xref>; Hasler et al. <xref ref-type="bibr" rid="CR24">2004</xref>; Hysek et al. <xref ref-type="bibr" rid="CR26">2011</xref>; Schmid et al. <xref ref-type="bibr" rid="CR43">2015</xref>; Vollenweider et al. <xref ref-type="bibr" rid="CR53">2007</xref>; Vollenweider and Kometer <xref ref-type="bibr" rid="CR52">2010</xref>). In addition to the subscale analyses, we also analyzed the effects on ego dissolution item 71 (the boundaries between myself and my surroundings seemed to blur) because the concept of ego dissolution was often used in recent imaging studies (Tagliazucchi et al. <xref ref-type="bibr" rid="CR49">2016</xref>). The 5D-ASC scale was administered 24&#x000a0;h after drug administration, and the participants were asked to retrospectively rate the drug effects. 5D-ASC ratings were also performed at 3 and 10&#x000a0;h in study 1.</p></sec></sec><sec id="Sec8"><title>Analysis of plasma LSD concentrations</title><p>Blood was collected into lithium heparin tubes before and 0.5, 1, 1.5, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24&#x000a0;h after LSD administration. The 0.5, 1.5, and 2.5&#x000a0;h samples were not collected in study 1. Blood samples were immediately centrifuged, and the plasma was rapidly stored at &#x02212;20&#x000a0;&#x000b0;C and later analyzed using liquid-chromatography-tandem mass-spectrometry as previously reported (Dolder et al. <xref ref-type="bibr" rid="CR11">2015a</xref>; Steuer et al. <xref ref-type="bibr" rid="CR45">2016</xref>). Maximal plasma concentrations (<italic>C</italic>
<sub>max</sub>) and total exposure (area under the plasma concentration-time curve [AUC]) were estimated using compartmental modeling in Phoenix WinNonlin 6.4 (Certara, Princeton, NJ, USA). A one-compartment model was used with first-order input, first-order elimination, and no lag time.</p></sec><sec id="Sec9"><title>Statistical analyses</title><p>The data analysis was performed using Statistica 12 software (StatSoft, Tulsa, OK, USA). Differences between LSD and placebo or between the 100 and 200&#x000a0;&#x003bc;g doses of LSD were compared using dependent or independent <italic>t</italic> tests, respectively. Associations between outcome measures were assessed using Pearson correlations. Significance was assumed at <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="Sec10" sec-type="results"><title>Results</title><sec id="Sec11"><title>Mystical-type experiences</title><p>LSD (200&#x000a0;&#x003bc;g) significantly increased all MEQ scores compared with placebo (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>, Table <xref rid="Tab1" ref-type="table">1</xref>). The effects of MDMA and methylphenidate on MEQ scores are included for comparison (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The effects of LSD (200&#x000a0;&#x003bc;g) and placebo on MEQ scores in 11 patients during LSD-assisted psychotherapy (Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>) are also shown in Fig. <xref rid="Fig1" ref-type="fig">1b</xref>. LSD-induced mystical experiences were comparable in healthy subjects in the laboratory setting in the present study and in patients in the therapeutic setting (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). Only two subjects in each of the studies had a complete mystical experience. The MEQ30 total scores were &#x0003c;5&#x000a0;% in both settings after placebo administration (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Effects of LSD on the Mystical Experience Questionnaire (MEQ). <bold>a</bold> In the present study in healthy subjects, LSD (200&#x000a0;&#x003bc;g) significantly increased scores on all scales of the MEQ43 and MEQ30 compared with placebo (Table <xref rid="Tab1" ref-type="table">1</xref>). The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 16 subjects. For comparison, 3,4-methylenedioxymethamphetamine (MDMA; 75&#x000a0;mg) and methylphenidate (40&#x000a0;mg) produced small increases in MEQ ratings in 30 different participants in another study in the same research setting (Schmid et al. <xref ref-type="bibr" rid="CR42">2014</xref>). <bold>b</bold> Effects of LSD on the MEQ in patients with anxiety in the context of life-threatening illness. The data were analyzed identically to the data that were obtained in the present study. The study and patient characteristics have been previously published in detail (Diesch <xref ref-type="bibr" rid="CR9">2015</xref>; Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>; Gasser et al. <xref ref-type="bibr" rid="CR16">2015</xref>; Schmid et al. <xref ref-type="bibr" rid="CR42">2014</xref>). Similar to the present study, the MEQ was administered on the day after LSD (200&#x000a0;&#x003bc;g) or active placebo (25&#x000a0;&#x003bc;g LSD) administration and was embedded into the larger 100-item States of Consciousness Questionnaire (SOCQ; Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>). The patient data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 11 subjects for LSD (200&#x000a0;&#x003bc;g, same formulation as in the present study) and four subjects for placebo. On the 43- and 30-item versions of the MEQ, LSD (200&#x000a0;&#x003bc;g) increased MEQ rating scores in the patients in the therapeutic setting <bold>(b)</bold> to a similar extent as in the healthy subjects in the present study <bold>(a)</bold>. Notably, the placebo response (a very low dose of LSD of 25&#x000a0;&#x003bc;g was used as the active placebo) in the patients was small <bold>(b)</bold>, which was also similar to the response in healthy subjects in the present study <bold>(a)</bold>
</p></caption><graphic xlink:href="213_2016_4453_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Statistics for the effects of LSD in the 5D-ASC and MEQ</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">LSD 100&#x000a0;&#x003bc;g<break/>
<italic>T</italic> test vs. placebo</th><th colspan="2">LSD 200&#x000a0;&#x003bc;g<break/>
<italic>T</italic> test vs. placebo</th><th colspan="2">LSD 100 vs. 200&#x000a0;&#x003bc;g<break/>
<italic>T</italic> test</th></tr><tr><th>
<italic>T</italic>=</th><th>
<italic>P=</italic>
</th><th>
<italic>T</italic>=</th><th>
<italic>P=</italic>
</th><th>
<italic>T</italic>=</th><th>
<italic>P=</italic>
</th></tr></thead><tbody><tr><td colspan="7">5 Dimensions Altered States of Consciousness (ASC) scale</td></tr><tr><td>&#x02003;Total ASC score</td><td>9.72</td><td>&#x0003c;0.001</td><td>10.02</td><td>&#x0003c;0.001</td><td>2.23</td><td align="center">&#x0003c;0.05</td></tr><tr><td>&#x02003;Oceanic boundlessness</td><td>8.44</td><td>&#x0003c;0.001</td><td>9.61</td><td>&#x0003c;0.001</td><td>1.89</td><td>NS</td></tr><tr><td>&#x02003;Anxious ego dissolution</td><td>6.43</td><td>&#x0003c;0.001</td><td>4.01</td><td>&#x0003c;0.001</td><td>1.50</td><td>NS</td></tr><tr><td>&#x02003;Visionary restructuralization</td><td>9.79</td><td>&#x0003c;0.001</td><td>15.32</td><td>&#x0003c;0.001</td><td>2.34</td><td align="center">&#x0003c;0.05</td></tr><tr><td>&#x02003;Auditory alterations</td><td>3.72</td><td align="right">&#x0003c;0.01</td><td>5.87</td><td>&#x0003c;0.001</td><td>0.42</td><td>NS</td></tr><tr><td>&#x02003;Reductions of vigilance</td><td>7.44</td><td>&#x0003c;0.001</td><td>5.93</td><td>&#x0003c;0.001</td><td>0.79</td><td>NS</td></tr><tr><td>&#x02003;Experience of unity</td><td>6.85</td><td>&#x0003c;0.001</td><td>7.77</td><td>&#x0003c;0.001</td><td>0.68</td><td>NS</td></tr><tr><td>&#x02003;Spiritual experience</td><td>4.31</td><td>&#x0003c;0.001</td><td>3.91</td><td>&#x0003c;0.001</td><td>1.10</td><td>NS</td></tr><tr><td>&#x02003;Blissful state</td><td>6.56</td><td>&#x0003c;0.001</td><td>8.27</td><td>&#x0003c;0.001</td><td>3.00</td><td align="center">&#x0003c;0.01</td></tr><tr><td>&#x02003;Insightfulness</td><td>4.11</td><td>&#x0003c;0.001</td><td>5.81</td><td>&#x0003c;0.001</td><td>2.28</td><td align="center">&#x0003c;0.05</td></tr><tr><td>&#x02003;Disembodiment</td><td>6.93</td><td>&#x0003c;0.001</td><td>5.87</td><td>&#x0003c;0.001</td><td>0.13</td><td>NS</td></tr><tr><td>&#x02003;Impaired control and cognition</td><td>7.01</td><td>&#x0003c;0.001</td><td>5.04</td><td>&#x0003c;0.001</td><td>0.86</td><td>NS</td></tr><tr><td>&#x02003;Anxiety</td><td>3.02</td><td>&#x0003c;0.001</td><td>2.04</td><td align="center">NS</td><td>1.37</td><td>NS</td></tr><tr><td>&#x02003;Complex imagery</td><td>7.10</td><td>&#x0003c;0.001</td><td>7.48</td><td>&#x0003c;0.001</td><td>0.31</td><td>NS</td></tr><tr><td>&#x02003;Elementary imagery</td><td>9.96</td><td>&#x0003c;0.001</td><td>11.12</td><td>&#x0003c;0.001</td><td>0.57</td><td>NS</td></tr><tr><td>&#x02003;Audio-visual synsthesia</td><td>9.19</td><td>&#x0003c;0.001</td><td>12.52</td><td>&#x0003c;0.001</td><td>1.96</td><td>NS</td></tr><tr><td>&#x02003;Changed meaning of percepts</td><td>6.25</td><td>&#x0003c;0.001</td><td>9.66</td><td>&#x0003c;0.001</td><td>3.39</td><td align="center">&#x0003c;0.01</td></tr><tr><td>&#x02003;Ego dissolution (item 71)</td><td>7.63</td><td>&#x0003c;0.001</td><td>5.32</td><td>&#x0003c;0.001</td><td>0.36</td><td>NS</td></tr><tr><td colspan="7">Mystical Effects Questionnaire (MEC43)</td></tr><tr><td>&#x02003;Internal unity</td><td align="right">NA</td><td align="right">NA</td><td>6.22</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;External unity</td><td align="right">NA</td><td align="right">NA</td><td>6.08</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Sacredness</td><td align="right">NA</td><td align="right">NA</td><td>6.80</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Noetic quality</td><td align="right">NA</td><td align="right">NA</td><td>5.71</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Deeply felt positive mood</td><td align="right">NA</td><td align="right">NA</td><td>11.43</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Transcendence of time/space</td><td align="right">NA</td><td align="right">NA</td><td>10.63</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Ineffability</td><td align="right">NA</td><td align="right">NA</td><td>16.22</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td colspan="7">Mystical Effects Questionnaire (MEQ30)</td></tr><tr><td>&#x02003;Mystical</td><td align="right">NA</td><td align="right">NA</td><td>5.99</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Positive mood</td><td align="right">NA</td><td align="right">NA</td><td>13.13</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Transcendence of time/space</td><td align="right">NA</td><td align="right">NA</td><td>11.12</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;Ineffability</td><td align="right">NA</td><td align="right">NA</td><td>25.14</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr><tr><td>&#x02003;MEC30 total score</td><td align="right">NA</td><td align="right">NA</td><td>14.91</td><td>&#x0003c;0.001</td><td>NA</td><td>NA</td></tr></tbody></table><table-wrap-foot><p>Sixteen subjects participated in the high-dose study (200&#x000a0;&#x003bc;g) and 24 subjects in the moderate-dose study (100&#x000a0;&#x003bc;g). Dependent <italic>T</italic> tests were performed to assess differences from placebo, and independent <italic>T</italic> tests were performed to assess differences between doses of <ext-link ext-link-type="uri" xlink:href="http://lsd.na">LSD</ext-link>
</p><p>
<ext-link ext-link-type="uri" xlink:href="http://lsd.na"><italic>NA</italic></ext-link> not assessed</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Alterations of consciousness</title><p>LSD induced pronounced peak alterations of waking consciousness, with significant increases in all dimensions and subscales of the 5D-ASC scale (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The 200&#x000a0;&#x003bc;g dose of LSD produced significantly greater scores on the overall ASC scale, the dimension of visionary restructuralization, and the blissful state, insightfulness, and changed meaning of percepts subscales compared with the 100&#x000a0;&#x003bc;g dose (Fig. <xref rid="Fig2" ref-type="fig">2</xref>, Table <xref rid="Tab1" ref-type="table">1</xref>). The mean&#x000a0;&#x000b1;&#x000a0;SEM ego dissolution (item 71) scores were 49&#x000a0;&#x000b1;&#x000a0;6 and 53&#x000a0;&#x000b1;&#x000a0;10 after the 100 and 200&#x000a0;&#x003bc;g doses, respectively (Table <xref rid="Tab1" ref-type="table">1</xref>). There were only minimal differences between the 5D-ASC ratings at 3, 10, and 24&#x000a0;h (supplementary Fig. <xref rid="MOESM1" ref-type="media">S1</xref> online).<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of LSD on the 5 Dimensions of Altered States of Consciousness (5D-ASC) scale. LSD mainly increased ratings of oceanic boundlessness (OB) and visionary restructuralization (VR), with significantly higher ratings for the ASC total score and VR dimension at 200&#x000a0;&#x003bc;g compared with 100&#x000a0;&#x003bc;g. LSD-induced increases in anxious ego dissolution (AED) and auditory alterations (AA) were relatively small. LSD also produced vigilance reduction (VIR). LSD-induced changes on the 5D-ASC scale were significant compared with placebo for both doses and all of the scales, with the exception of the effects of the 200&#x000a0;&#x003bc;g dose on anxiety (Table <xref rid="Tab1" ref-type="table">1</xref>). At 200&#x000a0;&#x003bc;g, LSD produced significant and relevantly higher ratings of blissful state, insightfulness, and changed meaning of percepts compared with 100&#x000a0;&#x003bc;g (<italic>one asterisk p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, <italic>two asterisks p</italic>&#x000a0;&#x0003c;&#x000a0;0.01, <italic>t</italic> tests). The data are expressed as the mean&#x000a0;&#x000b1;&#x000a0;SEM in 24 subjects and 16 subjects for the 100 and 200&#x000a0;&#x003bc;g doses of LSD, respectively</p></caption><graphic xlink:href="213_2016_4453_Fig2_HTML" id="MO2"/></fig>
</p></sec><sec id="Sec13"><title>Plasma LSD concentrations</title><p>Plasma concentrations varied between subjects, especially at the lower 100&#x000a0;&#x003bc;g dose. The median (range) <italic>C</italic>
<sub>max</sub> values were 1.4&#x000a0;ng/ml (0.32&#x02013;3.7) and 3.2&#x000a0;ng/ml (1.9&#x02013;7.1) for the 100 and 200&#x000a0;&#x003bc;g doses, respectively. The corresponding AUC values were 8.5&#x000a0;ng&#x000a0;&#x000d7;&#x000a0;h/ml (1&#x02013;19) and 20.7&#x000a0;ng&#x000a0;&#x000d7;&#x000a0;h/ml (11&#x02013;39).</p></sec><sec id="Sec14"><title>Associations between alterations of consciousness and mystical-type experiences</title><p>Table <xref rid="Tab2" ref-type="table">2</xref> shows the cross-tabulation of all correlations between the 5D-ASC scale and MEQ30 subscale ratings. LSD-induced alterations of consciousness (ASC total score) were significantly correlated with ratings of mystical experience (MEQ30 total score) on the MEQ (<italic>R</italic>
<sub><italic>p</italic></sub>&#x000a0;=&#x000a0;0.87, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;16; Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Scores on the MEQ positive mood scale were strongly associated with scores on the ASC experience of unity and blissful state scales (<italic>R</italic>
<sub><italic>p</italic></sub>&#x000a0;=&#x000a0;0.85 and 0.80, respectively; both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001, <italic>n</italic>&#x000a0;=&#x000a0;16; Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Associations between LSD-induced alterations in consciousness (5D-ASC) and mystical experiences (MEQ30)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="5">Mystical Effects Questionnaire (MEQ30)</th></tr><tr><th>MEQ30 total score</th><th>Mystical</th><th>Positive mood</th><th>Transcendence of time/space</th><th>Ineffability</th></tr></thead><tbody><tr><td colspan="6">5D-ASC scale</td></tr><tr><td>&#x02003;Total ASC score</td><td>
<italic>0.87</italic>
</td><td>
<bold>0.73</bold>
</td><td>
<bold>0.65</bold>
</td><td>
<italic>0.82</italic>
</td><td>
<bold>0.57</bold>
</td></tr><tr><td>&#x02003;Oceanic boundlessness</td><td>
<italic>0.93</italic>
</td><td>
<italic>0.88</italic>
</td><td>
<italic>0.83</italic>
</td><td>
<bold>0.74</bold>
</td><td>0.45</td></tr><tr><td>&#x02003;Anxious ego dissolution</td><td>
<bold>0.60</bold>
</td><td>0.39</td><td>0.35</td><td>
<bold>0.68</bold>
</td><td>
<bold>0.55</bold>
</td></tr><tr><td>&#x02003;Visionary restructuralization</td><td>
<bold>0.65</bold>
</td><td>
<bold>0.54</bold>
</td><td>0.38</td><td>
<bold>0.68</bold>
</td><td>0.45</td></tr><tr><td>&#x02003;Auditory alterations</td><td>0.30</td><td>0.14</td><td>0.02</td><td>0.49</td><td>0.38</td></tr><tr><td>&#x02003;Reductions of vigilance</td><td>
<bold>0.61</bold>
</td><td>0.41</td><td>0.47</td><td>
<bold>0.64</bold>
</td><td>0.47</td></tr><tr><td>&#x02003;Experience of unity</td><td>
<italic>0.82</italic>
</td><td>
<italic>0.86</italic>
</td><td>
<italic>0.85</italic>
</td><td>
<bold>0.56</bold>
</td><td>0.25</td></tr><tr><td>&#x02003;Spiritual experience</td><td>
<italic>0.79</italic>
</td><td>
<italic>0.76</italic>
</td><td>
<italic>0.76</italic>
</td><td>
<bold>0.60</bold>
</td><td>0.33</td></tr><tr><td>&#x02003;Blissful State</td><td>
<italic>0.80</italic>
</td><td>
<italic>0.77</italic>
</td><td>
<italic>0.80</italic>
</td><td>
<bold>0.72</bold>
</td><td>0.16</td></tr><tr><td>&#x02003;Insightfulness</td><td>
<italic>0.77</italic>
</td><td>
<italic>0.79</italic>
</td><td>
<bold>0.68</bold>
</td><td>
<bold>0.52</bold>
</td><td>0.42</td></tr><tr><td>&#x02003;Disembodiment</td><td>
<bold>0.71</bold>
</td><td>
<bold>0.53</bold>
</td><td>
<bold>0.62</bold>
</td><td>
<bold>0.71</bold>
</td><td>0.41</td></tr><tr><td>&#x02003;Impaired control and cognition</td><td>
<bold>0.63</bold>
</td><td>0.37</td><td>0.45</td><td>
<italic>0.79</italic>
</td><td>0.46</td></tr><tr><td>&#x02003;Anxiety</td><td>0.45</td><td>0.32</td><td>0.19</td><td>0.47</td><td>
<bold>0.51</bold>
</td></tr><tr><td>&#x02003;Complex imagery</td><td>0.48</td><td>0.31</td><td>0.32</td><td>
<bold>0.69</bold>
</td><td>0.19</td></tr><tr><td>&#x02003;Elementary imagery</td><td>0.36</td><td>0.37</td><td>0.08</td><td>0.29</td><td>0.42</td></tr><tr><td>&#x02003;Audio-visual synesthesia</td><td>0.23</td><td>0.07</td><td>0.22</td><td>0.45</td><td>&#x02212;0.01</td></tr><tr><td>&#x02003;Changed meaning of percepts</td><td>
<italic>0.80</italic>
</td><td>
<bold>0.67</bold>
</td><td>
<bold>0.59</bold>
</td><td>
<bold>0.70</bold>
</td><td>
<bold>0.63</bold>
</td></tr><tr><td>&#x02003;Ego dissolution (item 71)</td><td>
<bold>0.74</bold>
</td><td>
<bold>0.73</bold>
</td><td>
<bold>0.74</bold>
</td><td>
<bold>0.65</bold>
</td><td>0.12</td></tr></tbody></table><table-wrap-foot><p>Values are Pearson correlation coefficients in 16 subjects describing correlations between %5D-ASC and %MEQ30 scores. Bold values for <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, italic values for <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001</p></table-wrap-foot></table-wrap>
<fig id="Fig3"><label>Fig. 3</label><caption><p>LSD-induced alterations of consciousness are significantly associated with the LSD-induced mystical experience. The data are expressed as a percentage of ASC total scores on the 5D-ASC scale and a percentage of total scores on the MEQ30 for each of 16 participants after administration of 200&#x000a0;&#x003bc;g LSD. The <italic>lines</italic> indicate the regression and 95&#x000a0;% confidence intervals (<italic>R</italic>
<sub><italic>p</italic></sub>&#x000a0;=&#x000a0;0.87, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001)</p></caption><graphic xlink:href="213_2016_4453_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec15"><title>Correlations between plasma LSD concentrations and LSD-induced alterations of consciousness and mystical-type experiences</title><p>The <italic>C</italic>
<sub>max</sub> and AUC values for LSD were not positively correlated with ratings of peak subjective effects on the 5D-ASC scale or MEQ across subjects or within dose groups (Table <xref rid="Tab3" ref-type="table">3</xref>). For example, LSD induced consistently high ratings of audio-visual synesthesia in almost all of the subjects at the high dose (200&#x000a0;&#x003bc;g), resulting in little within-subject variance and no association with plasma exposure to LSD (Table <xref rid="Tab3" ref-type="table">3</xref>, Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). One exception was ego dissolution (item 71) at the lower dose of LSD (100&#x000a0;&#x003bc;g; Table <xref rid="Tab3" ref-type="table">3</xref>, Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). The ratings showed high interindividual variance, and there was a significant positive correlation with the LSD AUC value in the 100&#x000a0;&#x003bc;g dose group (<italic>R</italic>
<sub><italic>p</italic></sub>&#x000a0;=&#x000a0;0.51, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, <italic>n</italic>&#x000a0;=&#x000a0;16; Table <xref rid="Tab3" ref-type="table">3</xref>, Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). At the 200&#x000a0;&#x003bc;g dose, there were significant negative correlations between <italic>C</italic>
<sub>max</sub> values for LSD and subjective effects on the 5D-ASC scale including visionary restructuralization, elementary imagery, and changed meaning of percepts.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Associations between predicted maximal LSD plasma concentrations (<italic>C</italic>
<sub>max</sub>) and LSD exposure (AUC) and alterations in consciousness (SD-ASC) and mystical experiences (MEQ30)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th colspan="2">
<italic>N</italic>&#x000a0;=&#x000a0;24</th><th colspan="2">
<italic>N</italic>&#x000a0;=&#x000a0;16</th></tr><tr><th colspan="2">100&#x000a0;&#x003bc;g</th><th colspan="2">200&#x000a0;&#x003bc;g</th></tr><tr><th>
<italic>C</italic>
<sub>max</sub>
</th><th>AUC</th><th>
<italic>C</italic>
<sub>max</sub>
</th><th>AUC</th></tr></thead><tbody><tr><td colspan="5">5D-ASC scale</td></tr><tr><td>&#x02003;ASC total score</td><td>0.19</td><td>0.21</td><td>&#x02212;0.35</td><td>0.15</td></tr><tr><td>&#x02003;Oceanic boundlessness</td><td>0.24</td><td>0.26</td><td>&#x02212;0.35</td><td>0.10</td></tr><tr><td>&#x02003;Anxious ego dissolution</td><td>0.04</td><td>0.07</td><td>&#x02212;0.10</td><td>0.32</td></tr><tr><td>&#x02003;Visionary restructuralization</td><td>0.12</td><td>0.15</td><td>&#x02212;<bold>0.59</bold>
</td><td>&#x02212;0.16</td></tr><tr><td>&#x02003;Auditory alterations</td><td>0.02</td><td>0.12</td><td>&#x02212;0.18</td><td>0.08</td></tr><tr><td>&#x02003;Reductions of vigilance</td><td>&#x02212;0.01</td><td>0.13</td><td>&#x02212;0.10</td><td>0.38</td></tr><tr><td>&#x02003;Experience of unity</td><td>0.34</td><td>0.33</td><td>&#x02212;0.03</td><td>0.33</td></tr><tr><td>&#x02003;Spiritual experience</td><td>&#x02212;0.02</td><td>0.06</td><td>&#x02212;0.32</td><td>&#x02212;0.03</td></tr><tr><td>&#x02003;Blissful state</td><td>0.25</td><td>0.14</td><td>&#x02212;0.23</td><td>0.03</td></tr><tr><td>&#x02003;Insightfulness</td><td>0.24</td><td>0.20</td><td>&#x02212;0.37</td><td>0.12</td></tr><tr><td>&#x02003;Disembodiment</td><td>&#x02212;0.04</td><td>0.08</td><td>&#x02212;0.23</td><td>0.08</td></tr><tr><td>&#x02003;Impaired control and cognition</td><td>&#x02212;0.01</td><td>0.01</td><td>&#x02212;0.20</td><td>0.18</td></tr><tr><td>&#x02003;Anxiety</td><td>0.22</td><td>0.30</td><td>0.01</td><td>0.38</td></tr><tr><td>&#x02003;Complex imagery</td><td>0.06</td><td>0.14</td><td>&#x02212;0.28</td><td>&#x02212;0.04</td></tr><tr><td>&#x02003;Elementary imagery</td><td>&#x02212;0.13</td><td>&#x02212;0.03</td><td>&#x02212;<bold>0.53</bold>
</td><td>&#x02212;0.15</td></tr><tr><td>&#x02003;Audio-visual synesthesia</td><td>0.23</td><td>0.26</td><td>&#x02212;0.01</td><td>0.00</td></tr><tr><td>&#x02003;Changed meaning of percepts</td><td>&#x02212;0.03</td><td>&#x02212;0.06</td><td>&#x02212;<bold>0.62</bold>
</td><td>&#x02212;0.10</td></tr><tr><td>&#x02003;Ego dissolution (item 71)</td><td>0.40</td><td>
<bold>0.51</bold>
</td><td>&#x02212;0.27</td><td>&#x02212;0.14</td></tr><tr><td colspan="5">MEQ30</td></tr><tr><td>&#x02003;MEC30 total score</td><td align="right">NA</td><td/><td>&#x02212;0.30</td><td>0.17</td></tr><tr><td>&#x02003;Mystical</td><td align="right">NA</td><td/><td>&#x02212;0.25</td><td>0.13</td></tr><tr><td>&#x02003;Positive mood</td><td align="right">NA</td><td/><td>&#x02212;0.08</td><td>0.21</td></tr><tr><td>&#x02003;Transcendence of time/space</td><td align="right">NA</td><td/><td>&#x02212;0.23</td><td>0.10</td></tr><tr><td>&#x02003;Ineffability</td><td align="right">NA</td><td/><td>&#x02212;0.49</td><td>0.13</td></tr></tbody></table><table-wrap-foot><p>Values are Pearson correlation coefficients describing correlations, the peak concentrations of LSD predicted by the one-compartment model, and LSD-induced %5D-ASC and %MEQ30 scores. Bold values for <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05<italic>C</italic>
<sub><italic>max</italic></sub> maximal LSD plasma concentration predicted by the one-compartment pharmacokinetic model, <italic>AUC</italic> area under the LSD concentration-time curve predicted by the model</p></table-wrap-foot></table-wrap>
<fig id="Fig4"><label>Fig. 4</label><caption><p>Correlations between plasma LSD concentrations and subjective peak effects. <bold>a</bold> At 200&#x000a0;&#x003bc;g, LSD induced high ratings of audio-visual synesthesia in all but two of the 16 participants. There was little variance in the response and no correlation between total plasma exposure to LSD (area under the concentration-time curve [AUC]) and audio-visual synesthesia (<italic>R</italic>
<sub><italic>p</italic></sub>&#x000a0;=&#x000a0;0.0, <italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05, <italic>n</italic>&#x000a0;=&#x000a0;16). <bold>b</bold> In contrast, ego dissolution was present to highly variable degrees across subjects after administration of 100&#x000a0;&#x003bc;g LSD. Total exposure to LSD (AUC) positively correlated with LSD-induced ego dissolution (<italic>R</italic>
<sub><italic>p</italic></sub>&#x000a0;=&#x000a0;0.51, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, <italic>n</italic>&#x000a0;=&#x000a0;24). The <italic>lines</italic> indicate the regression and 95&#x000a0;% confidence intervals</p></caption><graphic xlink:href="213_2016_4453_Fig4_HTML" id="MO4"/></fig>
</p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p>The present study characterized LSD-induced mystical experiences using the MEQ after a dose of 200&#x000a0;&#x003bc;g and alterations of consciousness on the 5D-ASC scale after a dose of 100&#x000a0;&#x003bc;g. The study also evaluated associations between plasma LSD concentrations and these subjective effects.</p><p>LSD produced mean MEQ30 total score ratings of 61&#x000a0;% (range 40&#x02013;98&#x000a0;%) and a complete mystical experience in only two participants (12.5&#x000a0;%). The MEQ has typically been used with psilocybin, and data on MEQ30 scores are available for various doses of psilocybin, placebo, and methylphenidate (active placebo; Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>). Psilocybin (at the highest studied dose of 30&#x000a0;mg/70&#x000a0;kg) produced a high mean MEQ30 total score rating of 77&#x000a0;% and complete mystical experiences in as many as 67&#x000a0;% of healthy subjects (Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>). However, in this psilocybin study setting, inactive and active placebo (methylphenidate) also produced high mean MEQ30 ratings of 23 and 33&#x000a0;%, respectively (Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>). In contrast, in the present study, placebo increased MEQ30 scores only to 1&#x000a0;%. Similarly, MDMA and methylphenidate produced only small increases in MEQ scores in a similar laboratory setting (Schmid et al. <xref ref-type="bibr" rid="CR42">2014</xref>). Another study evaluated psilocybin-assisted psychotherapy in tobacco smokers and also found complete mystical experiences in only 10 of 26 sessions (38&#x000a0;%) that were conducted in 14 patients with high-dose psilocybin (30&#x000a0;mg/70&#x000a0;kg; Garcia-Romeu et al. <xref ref-type="bibr" rid="CR14">2015</xref>; Johnson et al. <xref ref-type="bibr" rid="CR27">2014</xref>). Accounting for the higher placebo ratings in some of the psilocybin studies compared with our study, LSD increased MEQ30 score differences from placebo overall more than psilocybin and produced greater ineffability and positive mood but lower effects on the mystical subscale than psilocybin (Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>).</p><p>Additionally, the MEQ has been used in patients with anxiety associated with life-threatening illness who were treated with 200&#x000a0;&#x003bc;g LSD (Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>; Gasser et al. <xref ref-type="bibr" rid="CR16">2015</xref>). In this therapeutic setting, LSD produced similar mystical experiences as in the present study and complete mystical experiences in only two of 11 patients. MEQ scores were only within the range of 3&#x02013;9&#x000a0;% after active placebo administration (25&#x000a0;&#x003bc;g LSD) on the MEQ subscales. Altogether, these findings indicate that mainly the placebo response and/or the expectancy of a mystical experience were greater in the study setting in some psilocybin studies compared with the&#x000a0;LSD studies. Additionally, the participants in the psilocybin studies may have been more spiritually inclined (Griffiths et al. <xref ref-type="bibr" rid="CR19">2006</xref>) than our study participants leading to more mystical experiences (Studerus et al. <xref ref-type="bibr" rid="CR48">2012</xref>). Furthermore, others may have provided more extensive preparation of the subjects and interpersonal support, contributing to mystical experiences.</p><p>The present findings do not support the view that LSD produces lower overall effects than psilocybin at the doses tested. In contrast, the high dose of LSD (200&#x000a0;&#x003bc;g) produced greater placebo-adjusted positive mood ratings than psilocybin on the MEQ30 (Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>) and very pronounced increases in 5D-ASC blissful state ratings and produced far greater effects than the highest doses of psilocybin or dimethyltryptamine (DMT) that were tested so far on this scale (Gouzoulis-Mayfrank et al. <xref ref-type="bibr" rid="CR17">2005</xref>; Hasler et al. <xref ref-type="bibr" rid="CR24">2004</xref>). Additionally, LSD-induced MEQ scores were highly correlated with 5D-ASC scores in the present study.</p><p>One could argue that mystical and spiritual experiences are not the most prominent feature of the LSD response. Mean ratings on the spiritual experience scale of the 5D-ASC were 22 and 33&#x000a0;% at the 100 and 200&#x000a0;&#x003bc;g doses, respectively, in the present study and approximately 23&#x000a0;% after 75&#x000a0;&#x003bc;g LSD in another study (Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>). Mean ratings of &#x0201c;the experience had a spiritual or mystical quality&#x0201d; were also only approximately 28&#x000a0;% in an imaging study that evaluated the effects of LSD (Tagliazucchi et al. <xref ref-type="bibr" rid="CR49">2016</xref>). However, a direct within-subjects comparison of LSD and psilocybin in the same research setting is needed to determine possible differences in mystical-type responses between these substances. Whether mystical-type experiences (Barrett et al. <xref ref-type="bibr" rid="CR1">2015</xref>; Garcia-Romeu et al. <xref ref-type="bibr" rid="CR14">2015</xref>; MacLean et al. <xref ref-type="bibr" rid="CR34">2011</xref>) are critical for the therapeutic potential of substance-assisted psychotherapy requires further study. At least in the case of LSD, the mystical experiences (MEQ scores) were highly associated with other alterations of consciousness on the 5D-ASC scale, and LSD produced additional effects on emotion processing that could facilitate psychotherapeutic interventions (Dolder et al. <xref ref-type="bibr" rid="CR13">2016</xref>).</p><p>Recent experimental studies associated the subjective effects of LSD (75&#x000a0;&#x003bc;g, intravenous) on the 5D-ASC scale with fMRI data but in the absence of data on plasma LSD levels (Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>; Kaelen et al. <xref ref-type="bibr" rid="CR29">2016</xref>; Lebedev et al. <xref ref-type="bibr" rid="CR33">2016</xref>; Roseman et al. <xref ref-type="bibr" rid="CR41">2016</xref>). Assuming high oral bioavailability of LSD of 70&#x02013;100&#x000a0;% (Dolder et al. <xref ref-type="bibr" rid="CR12">2015b</xref>), similar plasma exposure (AUC) can be assumed after oral administration of 100&#x000a0;&#x003bc;g LSD (present study I) or intravenous administration of 75&#x000a0;&#x003bc;g LSD (all studies by Carhart-Harris and colleagues). Supporting this assumption, the intravenous 75&#x000a0;&#x003bc;g dose of LSD produced very similar mean ratings on the 5D-ASC scale (Carhart-Harris et al. <xref ref-type="bibr" rid="CR6">2016b</xref>) to the present study that used an oral dose of 100&#x000a0;&#x003bc;g. In contrast, the 200&#x000a0;&#x003bc;g dose produced significantly greater ASC total scores and particularly greater 5D-ASC subscale scores of blissful state, insightfulness, and changed meaning of percepts. As previously reported, the 200&#x000a0;&#x003bc;g dose of LSD also produced greater feelings of closeness to others, happiness, openness, and trust than the 100&#x000a0;&#x003bc;g dose (Dolder et al. <xref ref-type="bibr" rid="CR13">2016</xref>). Altogether, the data indicate that the 200&#x000a0;&#x003bc;g dose produces overall greater effects and particularly more positive and MDMA-like effects than lower doses (Dolder et al. <xref ref-type="bibr" rid="CR13">2016</xref>). This is relevant because the higher dose is currently being used in LSD-assisted psychotherapy (Gasser et al. <xref ref-type="bibr" rid="CR15">2014</xref>; Gasser et al. <xref ref-type="bibr" rid="CR16">2015</xref>), and the lower dose is being tested in experimental fMRI studies (Carhart-Harris et al. <xref ref-type="bibr" rid="CR7">2016c</xref>). The 200&#x000a0;&#x003bc;g dose of LSD also produced greater ASC scores than high doses of the serotonergic hallucinogens DMT and psilocybin (Gouzoulis-Mayfrank et al. <xref ref-type="bibr" rid="CR17">2005</xref>; Hasler et al. <xref ref-type="bibr" rid="CR24">2004</xref>; Vollenweider and Kometer <xref ref-type="bibr" rid="CR52">2010</xref>), ketamine (Gouzoulis-Mayfrank et al. <xref ref-type="bibr" rid="CR17">2005</xref>; Studerus et al. <xref ref-type="bibr" rid="CR47">2010</xref>), and MDMA (Hysek et al. <xref ref-type="bibr" rid="CR26">2011</xref>), although direct comparisons within the same studies and subjects are missing.</p><p>The present analyses showed no positive correlations between LSD levels and effects across subjects, possibly because of the relatively high levels of LSD and generally consistently high subjective response ratings in most subjects. Thus, if relatively high and similar doses of LSD are used that result in plasma levels clearly above the EC<sub>50</sub> of a particular response measure, then it is unlikely that the response varies relevantly across subjects because responses are close to maximal. This would typically also be the case with measures with a maximal effect limit such as VAS ratings and some physiological effects like pupil size (Hysek and Liechti <xref ref-type="bibr" rid="CR25">2012</xref>).</p><p>In fact, responses to MDMA or LSD or other drugs in a standardized experimental setting may vary only if the response is not induced consistently in all subjects (e.g., at the beginning of the response) and are mostly attributable to individual differences in drug absorption/distribution (Hysek and Liechti <xref ref-type="bibr" rid="CR25">2012</xref>) or when a response is evaluated that is not robustly induced or when a lower dose is used. Specifically, correlations of plasma levels with the subjective and cardiovascular effects of MDMA across subjects are only weak during the peak response but stronger at onset (Hysek and Liechti <xref ref-type="bibr" rid="CR25">2012</xref>). This is an important consideration. For example, LSD-induced subjective ego dissolution was recently shown to be associated with specific brain activation patterns in a study that administered a relatively low dose of LSD of 75&#x000a0;&#x003bc;g intravenously (Tagliazucchi et al. <xref ref-type="bibr" rid="CR49">2016</xref>). Interestingly, LSD-induced ego dissolution correlated with plasma LSD levels after administration of an equivalent oral dose of 100&#x000a0;&#x003bc;g in the present study, and this was the only pharmacodynamic effect of LSD for which a positive association with plasma levels could be demonstrated across subjects. This finding needs to be kept in mind when interpreting associations between ego dissolution and fMRI parameters because the fMRI findings may also reflect other processes that are related to the plasma levels of LSD. Furthermore, the likelihood of detecting correlations within a dose group increases for effects that are not robustly induced in all subjects and thus for effects that are not typically present in all subjects after LSD administration. Finally, unclear is the extent to which a full LSD response was induced in the imaging studies that have been conducted to date because all of these studies used relatively low 75 or 100&#x000a0;&#x003bc;g doses. In the present study, the 200&#x000a0;&#x003bc;g dose of LSD produced particularly marked increases in visionary restructuralization including changed meaning of percepts which were significantly greater after the 200 compared with the 100&#x000a0;&#x003bc;g dose. Contrary to expectations, these perceptual alterations were greater in participants with relatively lower <italic>C</italic>
<sub>max</sub> levels of LSD within the 200&#x000a0;&#x003bc;g dose group further supporting the view that higher plasma levels of LSD may not produce greater subjective alterations above a certain threshold level and if high doses of LSD are used.</p><p>In conclusion, LSD (200&#x000a0;&#x003bc;g) rarely produced full mystical experiences in the present study and in patients during LSD-assisted psychotherapy compared with psilocybin in another set and setting. This raises questions regarding expectancy effects and placebo responses and the therapeutic role of mystical experiences. LSD produced significantly greater bliss, insightfulness, and changes in meaning of percepts at 200&#x000a0;&#x003bc;g compared with 100&#x000a0;&#x003bc;g, in addition to the previously reported greater empathogenic effects. This could be relevant for LSD-assisted psychotherapy (200&#x000a0;&#x003bc;g) and the interpretation of fMRI data (75&#x02013;100&#x000a0;&#x003bc;g). Generally, no association was found between plasma LSD levels and its robust effects when analyzed across different subjects and within a dose group. This may have implications for studies that interrelate different effects of LSD, namely fMRI studies.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec17"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="213_2016_4453_MOESM1_ESM.docx"><label>ESM 1</label><caption><p>(DOCX 202&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p>The studies were registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> (NCT02308969, NCT01878942).</p></fn><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:10.1007/s00213-016-4453-0) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><p>The authors thank Dr. Peter Gasser for providing MEQ data in patients and Michael Arends for text editing. MEL dedicated this work to Dr. Athina Markou, and thanks Drs. Athina Markou and Mark A. Geyer for their sincere support and mentorship.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><p>The studies were conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee. All of the subjects provided written consent before participating in either of the studies.</p><sec id="FPar3"><title>Conflict of interest</title><p>None.</p></sec><sec id="FPar4"><title>Funding</title><p>This work was supported by the Swiss National Science Foundation (grant no. 320030_170249 to MEL).</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin</article-title><source>J Psychopharmacol</source><year>2015</year><volume>29</volume><fpage>1182</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1177/0269881115609019</pub-id><pub-id pub-id-type="pmid">26442957</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>D</given-names></name><name><surname>Barnes</surname><given-names>G</given-names></name><name><surname>Giaroli</surname><given-names>G</given-names></name><name><surname>Tracy</surname><given-names>D</given-names></name></person-group><article-title>Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles</article-title><source>Ther Adv Psychopharmacol</source><year>2014</year><volume>4</volume><fpage>156</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1177/2045125314527985</pub-id><pub-id pub-id-type="pmid">25083275</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogenschutz</surname><given-names>MP</given-names></name><name><surname>Forcehimes</surname><given-names>AA</given-names></name><name><surname>Pommy</surname><given-names>JA</given-names></name><name><surname>Wilcox</surname><given-names>CE</given-names></name><name><surname>Barbosa</surname><given-names>PC</given-names></name><name><surname>Strassman</surname><given-names>RJ</given-names></name></person-group><article-title>Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study</article-title><source>J Psychopharmacol</source><year>2015</year><volume>29</volume><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1177/0269881114565144</pub-id><pub-id pub-id-type="pmid">25586396</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Whalley</surname><given-names>MG</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group><article-title>LSD enhances suggestibility in healthy volunteers</article-title><source>Psychopharmacology</source><year>2015</year><volume>232</volume><fpage>785</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1007/s00213-014-3714-z</pub-id><pub-id pub-id-type="pmid">25242255</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Rucker</surname><given-names>J</given-names></name><name><surname>Day</surname><given-names>CM</given-names></name><name><surname>Erritzoe</surname><given-names>D</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Bloomfield</surname><given-names>M</given-names></name><name><surname>Rickard</surname><given-names>JA</given-names></name><name><surname>Forbes</surname><given-names>B</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Pilling</surname><given-names>S</given-names></name><name><surname>Curran</surname><given-names>VH</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group><article-title>Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study</article-title><source>Lancet Psychiatry</source><year>2016</year><volume>3</volume><fpage>619</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/S2215-0366(16)30065-7</pub-id><pub-id pub-id-type="pmid">27210031</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name><name><surname>Underwood</surname><given-names>R</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group><article-title>The paradoxical psychological effects of lysergic acid diethylamide (LSD)</article-title><source>Psychol Med</source><year>2016</year><volume>46</volume><fpage>1379</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1017/S0033291715002901</pub-id><pub-id pub-id-type="pmid">26847689</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>S</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Droog</surname><given-names>W</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Schenberg</surname><given-names>EE</given-names></name><name><surname>Nest</surname><given-names>T</given-names></name><name><surname>Orban</surname><given-names>C</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name><name><surname>Williams</surname><given-names>TM</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Sessa</surname><given-names>B</given-names></name><name><surname>McGonigle</surname><given-names>J</given-names></name><name><surname>Sereno</surname><given-names>MI</given-names></name><name><surname>Nichols</surname><given-names>D</given-names></name><name><surname>Hellyer</surname><given-names>PJ</given-names></name><name><surname>Hobden</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>KD</given-names></name><name><surname>Wise</surname><given-names>RG</given-names></name><name><surname>Curran</surname><given-names>HV</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group><article-title>Neural correlates of the LSD experience revealed by multimodal neuroimaging</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><fpage>4853</fpage><lpage>4858</lpage><pub-id pub-id-type="doi">10.1073/pnas.1518377113</pub-id><pub-id pub-id-type="pmid">27071089</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>WJ</given-names></name></person-group><article-title>Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache</article-title><source>CMAJ</source><year>2016</year><volume>188</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.1503/cmaj.1150082</pub-id><pub-id pub-id-type="pmid">26883890</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Diesch</surname><given-names>MK</given-names></name></person-group><source>LSD: R&#x000fc;ckkehr in the Klinische Forschung</source><year>2015</year><publisher-loc>Solothurn</publisher-loc><publisher-name>Nachtschatten Verlag</publisher-name></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittrich</surname><given-names>A</given-names></name></person-group><article-title>The standardized psychometric assessment of altered states of consciousness (ASCs) in humans</article-title><source>Pharmacopsychiatry</source><year>1998</year><volume>31</volume><issue>Suppl 2</issue><fpage>80</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1055/s-2007-979351</pub-id><pub-id pub-id-type="pmid">9754838</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolder</surname><given-names>PC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Rentsch</surname><given-names>KM</given-names></name></person-group><article-title>Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases</article-title><source>Anal Bioanal Chem</source><year>2015</year><volume>407</volume><fpage>1577</fpage><lpage>1584</lpage><pub-id pub-id-type="doi">10.1007/s00216-014-8388-1</pub-id><pub-id pub-id-type="pmid">25542574</pub-id></element-citation></ref><ref id="CR12"><mixed-citation publication-type="other">Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015b) Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol 19. doi:10.1093/ijnp/pyv072</mixed-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolder</surname><given-names>PC</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Mueller</surname><given-names>F</given-names></name><name><surname>Borgwardt</surname><given-names>S</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>LSD acutely impairs fear recognition and enhances emotional empathy and sociality</article-title><source>Neuropsychopharmacology</source><year>2016</year><volume>41</volume><fpage>2638</fpage><lpage>2646</lpage><pub-id pub-id-type="doi">10.1038/npp.2016.82</pub-id><pub-id pub-id-type="pmid">27249781</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Romeu</surname><given-names>A</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name></person-group><article-title>Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction</article-title><source>Curr Drug Abuse Rev</source><year>2015</year><volume>7</volume><fpage>157</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.2174/1874473708666150107121331</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasser</surname><given-names>P</given-names></name><name><surname>Holstein</surname><given-names>D</given-names></name><name><surname>Michel</surname><given-names>Y</given-names></name><name><surname>Doblin</surname><given-names>R</given-names></name><name><surname>Yazar-Klosinski</surname><given-names>B</given-names></name><name><surname>Passie</surname><given-names>T</given-names></name><name><surname>Brenneisen</surname><given-names>R</given-names></name></person-group><article-title>Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases</article-title><source>J Nerv Ment Dis</source><year>2014</year><volume>202</volume><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1097/NMD.0000000000000113</pub-id><pub-id pub-id-type="pmid">24594678</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasser</surname><given-names>P</given-names></name><name><surname>Kirchner</surname><given-names>K</given-names></name><name><surname>Passie</surname><given-names>T</given-names></name></person-group><article-title>LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects</article-title><source>J Psychopharmacol</source><year>2015</year><volume>29</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1177/0269881114555249</pub-id><pub-id pub-id-type="pmid">25389218</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouzoulis-Mayfrank</surname><given-names>E</given-names></name><name><surname>Heekeren</surname><given-names>K</given-names></name><name><surname>Neukirch</surname><given-names>A</given-names></name><name><surname>Stoll</surname><given-names>M</given-names></name><name><surname>Stock</surname><given-names>C</given-names></name><name><surname>Obradovic</surname><given-names>M</given-names></name><name><surname>Kovar</surname><given-names>KA</given-names></name></person-group><article-title>Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers</article-title><source>Pharmacopsychiatry</source><year>2005</year><volume>38</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1055/s-2005-916185</pub-id><pub-id pub-id-type="pmid">16342002</pub-id></element-citation></ref><ref id="CR18"><mixed-citation publication-type="other">Griffiths R (2016) Overview of the Johns Hopkins psilocybin research project. Interdisciplinary Conference on Psychedelics Research, Amsterdam, June 3&#x02013;5, 2016</mixed-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Richards</surname><given-names>WA</given-names></name><name><surname>McCann</surname><given-names>U</given-names></name><name><surname>Jesse</surname><given-names>R</given-names></name></person-group><article-title>Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance</article-title><source>Psychopharmacology</source><year>2006</year><volume>187</volume><fpage>268</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0457-5</pub-id><pub-id pub-id-type="pmid">16826400</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>R</given-names></name><name><surname>Richards</surname><given-names>W</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>McCann</surname><given-names>U</given-names></name><name><surname>Jesse</surname><given-names>R</given-names></name></person-group><article-title>Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14&#x000a0;months later</article-title><source>J Psychopharmacol</source><year>2008</year><volume>22</volume><fpage>621</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1177/0269881108094300</pub-id><pub-id pub-id-type="pmid">18593735</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>RR</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Richards</surname><given-names>WA</given-names></name><name><surname>Richards</surname><given-names>BD</given-names></name><name><surname>McCann</surname><given-names>U</given-names></name><name><surname>Jesse</surname><given-names>R</given-names></name></person-group><article-title>Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects</article-title><source>Psychopharmacology</source><year>2011</year><volume>218</volume><fpage>649</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2358-5</pub-id><pub-id pub-id-type="pmid">21674151</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grob</surname><given-names>CS</given-names></name><name><surname>Danforth</surname><given-names>AL</given-names></name><name><surname>Chopra</surname><given-names>GS</given-names></name><name><surname>Hagerty</surname><given-names>M</given-names></name><name><surname>McKay</surname><given-names>CR</given-names></name><name><surname>Halberstadt</surname><given-names>AL</given-names></name><name><surname>Greer</surname><given-names>GR</given-names></name></person-group><article-title>Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer</article-title><source>Arch Gen Psych</source><year>2011</year><volume>68</volume><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.116</pub-id></element-citation></ref><ref id="CR23"><mixed-citation publication-type="other">Guss J (2016) The NYU School of Medicine study on psilocybin-assisted therapy for treatment of existential distress in cancer patients: history, study structure, therapist training, outcome data. Interdisciplinary Conference on Psychedelic Research Amsterdam 3&#x02013;5 June, 2016</mixed-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasler</surname><given-names>F</given-names></name><name><surname>Grimberg</surname><given-names>U</given-names></name><name><surname>Benz</surname><given-names>MA</given-names></name><name><surname>Huber</surname><given-names>T</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study</article-title><source>Psychopharmacology</source><year>2004</year><volume>172</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1007/s00213-003-1640-6</pub-id><pub-id pub-id-type="pmid">14615876</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Effects of MDMA alone and after pretreatement with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex</article-title><source>Psychopharmacology</source><year>2012</year><volume>224</volume><fpage>363</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1007/s00213-012-2761-6</pub-id><pub-id pub-id-type="pmid">22700038</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Ineichen</surname><given-names>M</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Brenneisen</surname><given-names>R</given-names></name><name><surname>Huwyler</surname><given-names>J</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans</article-title><source>Clin Pharmacol Ther</source><year>2011</year><volume>90</volume><fpage>246</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1038/clpt.2011.78</pub-id><pub-id pub-id-type="pmid">21677639</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Garcia-Romeu</surname><given-names>A</given-names></name><name><surname>Cosimano</surname><given-names>MP</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction</article-title><source>J Psychopharmacol</source><year>2014</year><volume>28</volume><fpage>983</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1177/0269881114548296</pub-id><pub-id pub-id-type="pmid">25213996</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Lorenz</surname><given-names>R</given-names></name><name><surname>Family</surname><given-names>N</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>HV</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>LSD enhances the emotional response to music</article-title><source>Psychopharmacology</source><year>2015</year><volume>232</volume><fpage>3607</fpage><lpage>3614</lpage><pub-id pub-id-type="doi">10.1007/s00213-015-4014-y</pub-id><pub-id pub-id-type="pmid">26257162</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Kahan</surname><given-names>J</given-names></name><name><surname>Santos-Ribeiro</surname><given-names>A</given-names></name><name><surname>Orban</surname><given-names>C</given-names></name><name><surname>Lorenz</surname><given-names>R</given-names></name><name><surname>Barrett</surname><given-names>FS</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name><name><surname>Wall</surname><given-names>MB</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>S</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name></person-group><article-title>LSD modulates music-induced imagery via changes in parahippocampal connectivity</article-title><source>Eur Neuropsychopharmacol</source><year>2016</year><volume>26</volume><fpage>1099</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2016.03.018</pub-id><pub-id pub-id-type="pmid">27084302</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>TS</given-names></name><name><surname>Johansen</surname><given-names>PO</given-names></name></person-group><article-title>Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials</article-title><source>J Psychopharmacol</source><year>2012</year><volume>26</volume><fpage>994</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1177/0269881112439253</pub-id><pub-id pub-id-type="pmid">22406913</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname><given-names>TS</given-names></name><name><surname>Johansen</surname><given-names>PO</given-names></name></person-group><article-title>Over 30 million psychedelic users in the United States</article-title><source>F1000Res</source><year>2013</year><volume>2</volume><fpage>98</fpage><pub-id pub-id-type="pmid">24627778</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupferschmidt</surname><given-names>K</given-names></name></person-group><article-title>High hopes</article-title><source>Science</source><year>2014</year><volume>345</volume><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1126/science.345.6192.18</pub-id><pub-id pub-id-type="pmid">24994630</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedev</surname><given-names>AV</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Lovden</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>LSD-induced entropic brain activity predicts subsequent personality change</article-title><source>Hum Brain Mapp</source><year>2016</year><volume>37</volume><fpage>3203</fpage><lpage>3213</lpage><pub-id pub-id-type="doi">10.1002/hbm.23234</pub-id><pub-id pub-id-type="pmid">27151536</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname><given-names>KA</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness</article-title><source>J Psychopharmacol</source><year>2011</year><volume>25</volume><fpage>1453</fpage><lpage>1461</lpage><pub-id pub-id-type="doi">10.1177/0269881111420188</pub-id><pub-id pub-id-type="pmid">21956378</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLean</surname><given-names>KA</given-names></name><name><surname>Leoutsakos</surname><given-names>JM</given-names></name><name><surname>Johnson</surname><given-names>MW</given-names></name><name><surname>Griffiths</surname><given-names>RR</given-names></name></person-group><article-title>Factor analysis of the Mystical Experience Questionnaire: a study of experiences occasioned by the hallucinogen psilocybin</article-title><source>J Sci Study Relig</source><year>2012</year><volume>51</volume><fpage>721</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1111/j.1468-5906.2012.01685.x</pub-id><pub-id pub-id-type="pmid">23316089</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>DE</given-names></name></person-group><article-title>Psychedelics</article-title><source>Pharmacol Rev</source><year>2016</year><volume>68</volume><fpage>264</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1124/pr.115.011478</pub-id><pub-id pub-id-type="pmid">26841800</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pahnke</surname><given-names>WN</given-names></name></person-group><article-title>Psychedelic drugs and mystical experience</article-title><source>Int Psychiatry Clin</source><year>1969</year><volume>5</volume><fpage>149</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">4892137</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pahnke</surname><given-names>WN</given-names></name><name><surname>Kurland</surname><given-names>AA</given-names></name><name><surname>Unger</surname><given-names>S</given-names></name><name><surname>Savage</surname><given-names>C</given-names></name><name><surname>Grof</surname><given-names>S</given-names></name></person-group><article-title>The experimental use of psychedelic (LSD) psychotherapy</article-title><source>JAMA</source><year>1970</year><volume>212</volume><fpage>1856</fpage><lpage>1863</lpage><pub-id pub-id-type="doi">10.1001/jama.1970.03170240060010</pub-id><pub-id pub-id-type="pmid">5467681</pub-id></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passie</surname><given-names>T</given-names></name><name><surname>Halpern</surname><given-names>JH</given-names></name><name><surname>Stichtenoth</surname><given-names>DO</given-names></name><name><surname>Emrich</surname><given-names>HM</given-names></name><name><surname>Hintzen</surname><given-names>A</given-names></name></person-group><article-title>The pharmacology of lysergic acid diethylamide: a review</article-title><source>CNS Neurosci Ther</source><year>2008</year><volume>14</volume><fpage>295</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1111/j.1755-5949.2008.00059.x</pub-id><pub-id pub-id-type="pmid">19040555</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickli</surname><given-names>A</given-names></name><name><surname>Moning</surname><given-names>OD</given-names></name><name><surname>Hoener</surname><given-names>MC</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens</article-title><source>Eur Neuropsychopharmacol</source><year>2016</year><volume>26</volume><fpage>1327</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2016.05.001</pub-id><pub-id pub-id-type="pmid">27216487</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Sereno</surname><given-names>MI</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Orban</surname><given-names>C</given-names></name><name><surname>McGonigle</surname><given-names>J</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion</article-title><source>Hum Brain Mapp</source><year>2016</year><volume>37</volume><fpage>3031</fpage><lpage>3040</lpage><pub-id pub-id-type="doi">10.1002/hbm.23224</pub-id><pub-id pub-id-type="pmid">27125770</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Hysek</surname><given-names>CM</given-names></name><name><surname>Simmler</surname><given-names>LD</given-names></name><name><surname>Crockett</surname><given-names>MJ</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Differential effects of MDMA and methylphenidate on social cognition</article-title><source>J Psychopharmacol</source><year>2014</year><volume>28</volume><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1177/0269881114542454</pub-id><pub-id pub-id-type="pmid">25052243</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Enzler</surname><given-names>F</given-names></name><name><surname>Gasser</surname><given-names>P</given-names></name><name><surname>Grouzmann</surname><given-names>E</given-names></name><name><surname>Preller</surname><given-names>KH</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Brenneisen</surname><given-names>R</given-names></name><name><surname>Muller</surname><given-names>F</given-names></name><name><surname>Borgwardt</surname><given-names>S</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Acute effects of lysergic acid diethylamide in healthy subjects</article-title><source>Biol Psychiatry</source><year>2015</year><volume>78</volume><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2014.11.015</pub-id><pub-id pub-id-type="pmid">25575620</pub-id></element-citation></ref><ref id="CR44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speth</surname><given-names>J</given-names></name><name><surname>Speth</surname><given-names>C</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Schloerscheidt</surname><given-names>AM</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>RL</given-names></name></person-group><article-title>Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide</article-title><source>J Psychopharmacol</source><year>2016</year><volume>30</volume><fpage>344</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1177/0269881116628430</pub-id><pub-id pub-id-type="pmid">26979587</pub-id></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steuer</surname><given-names>AE</given-names></name><name><surname>Poetzsch</surname><given-names>M</given-names></name><name><surname>Stock</surname><given-names>L</given-names></name><name><surname>Eisenbeiss</surname><given-names>L</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name><name><surname>Kraemer</surname><given-names>T</given-names></name></person-group><article-title>Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans</article-title><source>Drug Test Anal</source><year>2016</year></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strajhar</surname><given-names>P</given-names></name><name><surname>Schmid</surname><given-names>Y</given-names></name><name><surname>Liakoni</surname><given-names>E</given-names></name><name><surname>Dolder</surname><given-names>PC</given-names></name><name><surname>Rentsch</surname><given-names>KM</given-names></name><name><surname>Kratschmar</surname><given-names>DV</given-names></name><name><surname>Odermatt</surname><given-names>A</given-names></name><name><surname>Liechti</surname><given-names>ME</given-names></name></person-group><article-title>Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects</article-title><source>J Neuroendocrinol</source><year>2016</year><volume>28</volume><fpage>12374</fpage><pub-id pub-id-type="doi">10.1111/jne.12374</pub-id><pub-id pub-id-type="pmid">26849997</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studerus</surname><given-names>E</given-names></name><name><surname>Gamma</surname><given-names>A</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Psychometric evaluation of the altered states of consciousness rating scale (OAV)</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><pub-id pub-id-type="doi">10.1371/journal.pone.0012412</pub-id><pub-id pub-id-type="pmid">20824211</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studerus</surname><given-names>E</given-names></name><name><surname>Gamma</surname><given-names>A</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name><name><surname>Vollenweider</surname><given-names>FX</given-names></name></person-group><article-title>Prediction of psilocybin response in healthy volunteers</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e30800</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0030800</pub-id><pub-id pub-id-type="pmid">22363492</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagliazucchi</surname><given-names>E</given-names></name><name><surname>Roseman</surname><given-names>L</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Orban</surname><given-names>C</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>SD</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Laufs</surname><given-names>H</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>McGonigle</surname><given-names>J</given-names></name><name><surname>Crossley</surname><given-names>N</given-names></name><name><surname>Bullmore</surname><given-names>E</given-names></name><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name></person-group><article-title>Increased global functional connectivity correlates with LSD-induced ego dissolution</article-title><source>Curr Biol</source><year>2016</year><volume>26</volume><fpage>1043</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2016.02.010</pub-id><pub-id pub-id-type="pmid">27085214</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terhune</surname><given-names>DB</given-names></name><name><surname>Luke</surname><given-names>DP</given-names></name><name><surname>Kaelen</surname><given-names>M</given-names></name><name><surname>Bolstridge</surname><given-names>M</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Nutt</surname><given-names>D</given-names></name><name><surname>Carhart-Harris</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name></person-group><article-title>A placebo-controlled investigation of synaesthesia-like experiences under LSD</article-title><source>Neuropsychologia</source><year>2016</year><volume>88</volume><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2016.04.005</pub-id><pub-id pub-id-type="pmid">27059209</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turek</surname><given-names>IS</given-names></name><name><surname>Soskin</surname><given-names>RA</given-names></name><name><surname>Kurland</surname><given-names>AA</given-names></name></person-group><article-title>Methylenedioxyamphetamine (MDA)-subjective effects</article-title><source>J Psychoactive Drugs</source><year>1974</year><volume>6</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/02791072.1974.10471499</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Kometer</surname><given-names>M</given-names></name></person-group><article-title>The neurobiology of psychedelic drugs: implications for the treatment of mood disorders</article-title><source>Nat Rev Neurosci</source><year>2010</year><volume>11</volume><fpage>642</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1038/nrn2884</pub-id><pub-id pub-id-type="pmid">20717121</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollenweider</surname><given-names>FX</given-names></name><name><surname>Csomor</surname><given-names>PA</given-names></name><name><surname>Knappe</surname><given-names>B</given-names></name><name><surname>Geyer</surname><given-names>MA</given-names></name><name><surname>Quednow</surname><given-names>BB</given-names></name></person-group><article-title>The effects of the preferential 5-HT<sub>2A</sub> agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval</article-title><source>Neuropsychopharmacology</source><year>2007</year><volume>32</volume><fpage>1876</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301324</pub-id><pub-id pub-id-type="pmid">17299516</pub-id></element-citation></ref></ref-list></back></article>